Midazolam
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Buccolam | — | 2011-09-04 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | VERSED | — | 1994-04-26 – 1997-03-18 | fda.gov ↗ |
| Approved | US (FDA) | VERSED | — | 1985-12-20 | fda.gov ↗ |
Trials 639 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 013 trials | ||||||
| Phase 0 | NCT05264077 | Nov 2024 → Jun 2025 overdue | — | Sheikh Zayed Medical College | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06693960 | Sep 2024 → Dec 2026 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT06215768 | Jan → Sep 2024 | delirium | Esraa Abdel Azez Soltan Mohamed Zayed | Unknown | No outcome recorded |
| Phase 0 | NCT05891119 | Jun 2023 → Aug 2024 | atopic eczema | Amgen | Completed | No outcome recorded |
| Phase 0 | NCT05505630 | Jan 2023 → Dec 2025 | nicotine dependence | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT05574179 | Jan → Jul 2023 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT05579509 | Oct 2022 → May 2024 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04807101 | Apr 2021 → Jul 2023 | — | Greg S Cohen MD LLC | Completed | No outcome recorded |
| Phase 0 | NCT04718259 | Jan 2020 → Feb 2021 | — | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT06271096 | Nov 2019 → Nov 2022 | epilepsy | Arooj Khan | Completed | No outcome recorded |
| Phase 0 | NCT04392011 | Oct 2019 → Aug 2021 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT03772262 | Apr → Nov 2018 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT03049293 | Jun 2017 → Oct 2019 | — | ART Fertility Clinics LLC | Terminated | No outcome recorded |
| Phase 1402 trials | ||||||
| Phase 1 | NCT07710768 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07665723 | Jun 2026 → Jul 2027 expected | ulcerative colitis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT07685041 | Jun → Nov 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07670377 | Jun → Aug 2026 overdue | Plasmodium falciparum malaria | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07660731 | Jun 2026 → Jun 2027 expected | asthma | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07340190 | Jun 2026 → Mar 2028 expected | cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07608705 | Jun → Aug 2026 overdue | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07570082 | May → Dec 2026 expected | — | Crinetics Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07584434 | May 2026 → Mar 2027 expected | narcolepsy 1 | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 1 | NCT07426757 | May 2026 → Jul 2029 expected | cancer | Pfizer | Recruiting | No outcome recorded |
| Show all 402 trials opens the full record — a long page | ||||||
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT05384626 | Jun 2022 → Dec 2027 expected | metastatic neoplasm | Nuvalent Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04586504 | Sep 2021 → May 2024 | anxiety | Columbia University | Completed | No outcome recorded |
| Phase 1/2 | NCT04141696 | Jul 2021 → Mar 2024 | — | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 1/2 | NCT03760445 | Nov 2019 → Jul 2021 | acute myeloid leukemia | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04044001 | Nov 2019 → Mar 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 1/2 | NCT04067336 | Sep 2019 → Oct 2028 expected | mixed phenotype acute leukemia with MLL rearranged | Kura Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03813121 | Jun 2019 → Aug 2021 | nicotine dependence | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT03600883 | Aug 2018 → May 2026 | — | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT03535168 | May 2018 → Sep 2019 | — | Bayer | Completed | No outcome recorded |
| Phase 1/2 | NCT03436485 | Mar 2018 → Jul 2026 overdue | prostate cancer | Orion Corporation, Orion Pharma | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02014558 | Oct 2013 → Aug 2017 | acute myeloid leukemia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02050893 | May 2012 → Apr 2013 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT05945147 | Jan → Apr 2099 | complex regional pain syndrome | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07668700 | Dec 2025 → Jun 2026 | — | Hameed Latif Hospital, Lahore | Completed | No outcome recorded |
| Phase 2 | NCT07519863 | Nov 2025 → Nov 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2 | NCT05057689 | Sep → Oct 2025 | acute stress disorder, anxiety | Nationwide Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06638710 | Jul 2025 → Jun 2026 overdue | cognitive disorder | University Hospital, Grenoble | Recruiting | No outcome recorded |
| Phase 2 | NCT06979791 | Jun → Sep 2025 overdue | — | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07620912 | Apr 2025 → Apr 2026 | chronic obstructive pulmonary disease, respiratory failure | Al-Azhar University | Completed | No outcome recorded |
| Phase 2 | NCT06111872 | Jul 2023 → Feb 2024 | bile duct cyst, cholangitis, choledocholithiasis, malignant pancreatic neoplasm | National University of Malaysia | Completed | No outcome recorded |
| Phase 2 | NCT05378100 | Jan 2023 → May 2026 overdue | myalgic encephalomeyelitis/chronic fatigue syndrome | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04562116 | Dec 2021 → Jun 2023 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT03959566 | May 2021 → Sep 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 2 | NCT04557449 | Sep 2020 → Sep 2026 expected | breast neoplasm, liposarcoma, lung adenocarcinoma, prostate cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02232139 | Mar 2016 → Jun 2019 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 2 | NCT04608734 | Jun 2015 → Jun 2016 | — | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2 | NCT02365597 | Apr 2015 → Sep 2022 overdue | urothelial carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01948908 | Jun 2013 → Sep 2015 | — | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT01441505 | Sep 2011 → Dec 2014 | major depressive disorder | The University of New South Wales | Unknown | No outcome recorded |
| Phase 2 | NCT00942539 | Jul 2009 → Jul 2011 | anxiety | Rambam Health Care Campus | Terminated | No outcome recorded |
| Phase 2 | NCT00869440 | Mar → Sep 2009 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00176670 | Jan 2004 → Apr 2006 | anxiety | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00248729 | Oct 2002 → Nov 2005 | respiratory failure | St. Luke's Hospital, Pennsylvania | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07095842 | Aug 2025 → Jul 2026 overdue | epilepsy syndrome | Sohag University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06752616 | Dec 2024 → Dec 2027 expected | — | Lone Baandrup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05883150 | Nov 2022 → Aug 2023 | — | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2/3 | NCT02713191 | Mar 2016 → Feb 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT01275547 | Jan → Jun 2011 | spinal stenosis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2/3 | NCT00125424 | Jul → Sep 2005 | polyp of colon | Eisai Inc. | Completed | No outcome recorded |
| Phase 328 trials | ||||||
| Phase 3 | NCT07155265 | Oct 2025 → Jun 2027 expected | respiratory failure | Yancheng First People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07019805 | Sep 2024 → Mar 2025 | acute hypotension | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT06383273 | May → Dec 2024 overdue | cataract | Melt Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05383495 | Dec 2023 → Dec 2025 overdue | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 3 | NCT05646862 | Jun 2023 → Nov 2026 expected | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05681572 | Apr 2023 → Oct 2027 expected | — | University Hospital, Montpellier | Recruiting | No outcome recorded |
| Phase 3 | NCT05324852 | Apr 2023 | delirium | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT05121324 | Aug 2022 → Jul 2026 overdue | epilepsy | Stanford University | Recruiting | No outcome recorded |
| Phase 3 | NCT05208047 | Apr 2022 → Sep 2025 overdue | gastrointestinal stromal tumor, metastatic malignant neoplasm | Cogent Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05126459 | Feb 2022 → Apr 2023 | anxiety, dental caries | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT04571879 | Aug 2021 → Dec 2023 | anxiety | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT04134052 | Jan → May 2021 | cognitive disorder | University of Colima | Unknown | No outcome recorded |
| Phase 3 | NCT04160611 | Sep 2019 → Jun 2020 | — | University Hospital Sestre Milosrdnice | Unknown | No outcome recorded |
| Phase 3 | NCT03336450 | Apr 2018 → Oct 2020 | nervous system disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT03483350 | Mar → Aug 2018 | — | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT04276545 | Jan 2018 → Mar 2020 | hemorrhagic disease | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT03336645 | Oct 2017 → Aug 2019 | nervous system disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02161185 | May 2014 → May 2015 | epilepsy | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 3 | NCT01999777 | Nov 2013 → Aug 2015 | epilepsy | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT01529034 | Jul 2012 → Apr 2017 | epilepsy | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 3 | NCT01462318 | Nov 2011 → Jan 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT01390220 | Jun 2011 → Mar 2017 | epilepsy | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 3 | NCT00416039 | Jan 2007 → Nov 2008 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01731184 | Nov 2006 → Sep 2009 | — | Centre Hospitalier de Cornouaille | Completed | No outcome recorded |
| Phase 3 | NCT00261599 | Mar → Oct 2006 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01874717 | Jun 2005 → Aug 2007 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 3 | NCT00221520 | Feb 2003 → Jan 2007 | respiratory failure | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase 476 trials | ||||||
| Phase 4 | NCT07704658 | Jun 2026 → Jul 2027 expected | non-small cell lung carcinoma, thyroid cancer | Rigel Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT07556523 | Mar 2026 → Apr 2028 expected | aortic valve stenosis | David Lyubashevsky | Recruiting | No outcome recorded |
| Phase 4 | NCT07300826 | Jan 2026 → Feb 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06763705 | Jun → Dec 2025 | — | Qassim Health Cluster | Completed | No outcome recorded |
| Phase 4 | NCT07190612 | Dec 2024 → Apr 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT06887712 | Apr → Dec 2024 | — | Hanoi Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05934669 | Nov 2023 → May 2025 | anxiety | University of Oklahoma | Unknown | No outcome recorded |
| Phase 4 | NCT06273215 | Mar 2023 → Dec 2025 | diabetes mellitus | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05874245 | Mar 2023 → Mar 2024 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 4 | NCT05707234 | Feb → Aug 2023 | anxiety disorder, osteoarthritis, knee | University of Liege | Completed | No outcome recorded |
| Phase 4 | NCT05469204 | Nov 2022 → Jul 2025 | — | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05553678 | Sep 2022 → Sep 2023 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05747768 | Jul 2022 → Jun 2024 | chronic kidney disease | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05368441 | May → Dec 2022 | — | Karaman Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05369819 | May 2022 → Jan 2024 | — | Karaman Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05994547 | Apr 2022 → Jun 2023 | — | Chungbuk National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05045378 | Mar 2022 → Nov 2024 | major depressive disorder | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT04885075 | May → Nov 2021 | epilepsy | Shaheed Zulfiqar Ali Bhutto Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT06315634 | Mar 2021 → Mar 2022 | — | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 4 | NCT04119180 | Jan 2020 → Feb 2025 overdue | dental caries | Federal University of Goiás | Recruiting | No outcome recorded |
| Phase 4 | NCT04174872 | Dec 2019 → Feb 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03933007 | Sep → Oct 2019 | gout | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT03809442 | Jun 2019 → Aug 2023 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 4 | NCT03534895 | May 2019 → May 2020 | neuropathy, painful | University of Porto | Unknown | No outcome recorded |
| Phase 4 | NCT05670509 | Jan 2019 → Jul 2022 | epilepsy | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03394430 | Oct → Dec 2018 | — | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Unknown | No outcome recorded |
| Phase 4 | NCT03960671 | Aug 2018 → Dec 2022 | — | Wei Zhao | Unknown | No outcome recorded |
| Phase 4 | NCT04248335 | Jul 2018 → Dec 2024 | gastroesophageal reflux disease, metabolic dysfunction-associated steatotic liver disease | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 4 | NCT03246724 | Oct 2017 → Nov 2019 | — | Boston Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03052660 | Oct 2017 → Jun 2019 | — | RWTH Aachen University | Completed | No outcome recorded |
| Phase 4 | NCT03204578 | Aug → Sep 2017 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT03284307 | Aug 2017 → Mar 2020 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT02856698 | Apr 2017 → Dec 2020 | pulmonary edema | Alberto Dominguez-Rodriguez | Terminated | No outcome recorded |
| Phase 4 | NCT02009306 | Jan 2017 → Feb 2018 | — | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT03029676 | Jan → Dec 2017 | urinary bladder neoplasm | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT02985697 | Jan 2017 → Jan 2018 | — | Bon Secours Pediatric Dental Associates | Unknown | No outcome recorded |
| Phase 4 | NCT02760615 | Nov 2016 → Aug 2020 | Crohn disease, ulcerative colitis | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT03551067 | Aug 2016 → Dec 2017 | adenoid hypertrophy | Suez Canal University | Completed | No outcome recorded |
| Phase 4 | NCT02909465 | Jul 2016 → Apr 2017 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02629146 | Dec 2015 → Mar 2016 | — | Wilhelminenspital Vienna | Completed | No outcome recorded |
| Phase 4 | NCT02528513 | Dec 2015 → Dec 2016 | delirium | West China Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02579928 | Oct 2015 → Sep 2018 | anxiety disorder, major depressive disorder | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT02634021 | Jul 2015 → Jul 2018 | osteoarthritis, knee | Konkuk University Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02447289 | May 2015 → Oct 2016 | dental caries | Federal University of Goiás | Completed | No outcome recorded |
| Phase 4 | NCT02475824 | May 2015 → Nov 2016 | — | Dankook University | Completed | No outcome recorded |
| Phase 4 | NCT02486328 | May → Jun 2015 | cognitive disorder, digestive system disorder | Ufuk University | Completed | No outcome recorded |
| Phase 4 | NCT02291666 | Apr 2015 → Jul 2019 | type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT02296073 | Dec 2014 | — | Anhui Provincial Children's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03791424 | Oct 2014 → Jun 2015 | — | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT02233972 | Aug → Oct 2014 | — | Jiangsu Kanion Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02122055 | Jun 2014 → Apr 2015 | — | Tianjin Third Central Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02168439 | Jun 2014 → Apr 2015 | anxiety | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT02142595 | May → Dec 2014 | — | China Medical University, China | Completed | No outcome recorded |
| Phase 4 | NCT02135055 | May 2014 → Mar 2015 | immune system disorder, infectious disease with sepsis | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02123589 | Apr 2014 → May 2015 | substance withdrawal syndrome | West China Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02166853 | Apr 2014 → Feb 2016 | acute respiratory distress syndrome | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT01993459 | Feb 2014 → Oct 2015 | anxiety, depressive disorder | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02080169 | Feb → Dec 2014 | delirium | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT02078336 | Dec 2013 → Jul 2025 overdue | — | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02937506 | Nov 2013 → Mar 2016 | colon carcinoma, irritable bowel syndrome, polyp | Mount Carmel Health System | Completed | No outcome recorded |
| Phase 4 | NCT02071407 | Oct 2013 → Mar 2015 | traumatic brain injury | Subei People's Hospital of Jiangsu Province | Unknown | No outcome recorded |
| Phase 4 | NCT02027311 | Apr → Aug 2013 | cholangiocarcinoma, choledocholithiasis, malignant pancreatic neoplasm, pancreatitis | Cheju Halla General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01766050 | Jan → Apr 2013 | transplant rejection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01519726 | Dec 2011 → Dec 2013 | morbid obesity | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01375634 | May 2011 → Apr 2013 | — | University of Vermont | Completed | No outcome recorded |
| Phase 4 | NCT01321047 | Apr → Sep 2011 | — | Soon Chun Hyang University | Unknown | No outcome recorded |
| Phase 4 | NCT00952653 | Jun → Aug 2010 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00947791 | Jul → Oct 2009 | bipolar disorder | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 4 | NCT00871039 | Mar 2009 | alcohol-related disorders | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00577200 | Jan 2008 → Nov 2026 expected | — | Rush University Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT00158873 | Sep 2004 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00596414 | May 2003 → Oct 2005 | anxiety, cirrhosis of liver, hepatitis | Erasme University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00050180 | Nov 2002 → Aug 2007 | HIV infectious disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 4 | NCT00188227 | Sep 2001 → Nov 2003 | — | Technical University Dresden | Completed | No outcome recorded |
| Phase 4 | NCT00440960 | — | lung cancer | Hospital Pompeia | Completed | No outcome recorded |
| Phase not applicable81 trials | ||||||
| — | NCT07622641 | Aug 2026 → Aug 2027 expected | adenoid hypertrophy | Erzurum City Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07678216 | Jul 2026 → Jun 2028 expected | traumatic brain injury | Aswan University | Not yet recruiting | No outcome recorded |
| — | NCT07699523 | Jun 2026 → Jun 2027 expected | electroencephalographic peculiarity: fronto-precentral beta wave groups | China-Japan Friendship Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07498387 | Jan → Aug 2026 overdue | autism spectrum disorder, catatonia | Tanta University | Active not recruiting | No outcome recorded |
| — | NCT07347886 | Jan → Jul 2026 overdue | cataract | Istanbul University - Cerrahpasa | Not yet recruiting | No outcome recorded |
| — | NCT07198412 | Oct 2025 → Apr 2026 overdue | chronic pain syndrome | Benha University | Recruiting | No outcome recorded |
| — | NCT07166666 | Sep 2025 → Sep 2026 expected | — | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| — | NCT07392983 | Jul → Dec 2025 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06549426 | Apr 2025 → Dec 2029 expected | epilepsy | University of Twente | Recruiting | No outcome recorded |
| — | NCT07564037 | Nov 2024 → Nov 2025 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07580768 | Nov 2024 → Oct 2025 | — | Tanta University | Completed | No outcome recorded |
| — | NCT06407518 | Jul 2024 → Oct 2025 overdue | anxiety, sleep disorder | Sixth Affiliated Hospital, Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06373627 | May 2024 → May 2025 | congenital heart disease | Fondation Hôpital Saint-Joseph | Unknown | No outcome recorded |
| — | NCT06464263 | Feb 2024 → Feb 2026 | cardiac valvular defect | Egymedicalpedia | Unknown | No outcome recorded |
| — | NCT06203405 | Dec 2023 → Mar 2026 overdue | acute lung injury, adult acute respiratory distress syndrome | Siriraj Hospital | Recruiting | No outcome recorded |
| — | NCT05741385 | Oct 2023 → Aug 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT06018207 | Sep → Oct 2023 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT05863455 | May 2023 → Oct 2024 | — | Affiliated Hospital of Jiaxing University | Completed | No outcome recorded |
| — | NCT06056349 | May 2023 → Dec 2024 | epilepsy | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Unknown | No outcome recorded |
| — | NCT06389318 | Mar 2023 → Mar 2024 | hernia, double inguinal | Benha University | Completed | No outcome recorded |
| — | NCT07072117 | Feb → Aug 2023 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT05398757 | Jul 2022 → Mar 2024 | — | Osijek University Hospital | Withdrawn | No outcome recorded |
| — | NCT04887285 | Mar 2022 → Aug 2023 | radiculopathy | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT05057767 | Sep 2021 → Jun 2022 | — | Benha University | Completed | No outcome recorded |
| — | NCT04932083 | Jun 2021 → Jan 2022 | — | Benha University | Completed | No outcome recorded |
| — | NCT05518799 | Apr 2021 → Dec 2022 | prostate cancer | The Netherlands Cancer Institute | Completed | No outcome recorded |
| — | NCT07021521 | Apr 2021 → Apr 2023 | preeclampsia | Zhuji People's Hospital of Zhejiang Province | Completed | No outcome recorded |
| — | NCT04266340 | Dec 2020 → Nov 2021 | — | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT03984240 | Nov 2020 → Jul 2023 | brain glioma | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT04601350 | Nov 2020 → May 2022 | — | Yangzhou University | Completed | No outcome recorded |
| — | NCT05417529 | Mar 2020 | oral cavity carcinoma | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | Completed | No outcome recorded |
| — | NCT04284150 | Feb → Jun 2020 | — | Lianyungang Hospital Affiliated Bengbu Medical College | Unknown | No outcome recorded |
| — | NCT04018703 | Nov 2019 → Jul 2021 | — | Eye & ENT Hospital of Fudan University | Unknown | No outcome recorded |
| — | NCT04232150 | Jun → Oct 2019 | — | University of Jordan | Completed | No outcome recorded |
| — | NCT03918889 | May 2019 → Dec 2020 | — | Eye & ENT Hospital of Fudan University | Unknown | No outcome recorded |
| — | NCT03813043 | Feb → Nov 2019 | gastroesophageal reflux disease | King Fahad Specialist Hospital Dammam | Unknown | No outcome recorded |
| — | NCT03830086 | Feb → Apr 2019 | — | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | No outcome recorded |
| — | NCT05290324 | Feb 2019 → Feb 2020 | coronary artery disorder | Chaudhry Pervaiz Elahi Institute of Cardiology | Completed | No outcome recorded |
| — | NCT03778723 | Dec 2018 → Dec 2019 | brain aneurysm | Mansoura University | Completed | No outcome recorded |
| — | NCT03738137 | Aug 2018 → Jan 2019 | — | Guangzhou Institute of Respiratory Disease | Completed | No outcome recorded |
| — | NCT03388957 | Jul 2018 → Oct 2019 | — | Damascus University | Completed | No outcome recorded |
| — | NCT03603119 | May 2018 → Nov 2019 | — | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT03337945 | Apr 2018 → Jun 2021 | cirrhosis of liver | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT03401736 | Mar 2018 → Oct 2020 | — | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Withdrawn | No outcome recorded |
| — | NCT03406533 | Feb → Mar 2018 | — | Changhai Hospital | Terminated | No outcome recorded |
| — | NCT03293342 | Sep 2017 → Nov 2020 | — | University of Oslo | Unknown | No outcome recorded |
| — | NCT03653520 | Jun → Nov 2017 | cataract | Avanti Anesthesia | Completed | No outcome recorded |
| — | NCT03343873 | Apr 2017 → Dec 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT02966743 | Nov 2016 → Oct 2017 | brain hypoxia - ischemia | Gachon University Gil Medical Center | Withdrawn | No outcome recorded |
| — | NCT03678532 | Jul 2016 → Nov 2017 | — | Assiut University | Completed | No outcome recorded |
| — | NCT02590185 | Dec 2015 → Dec 2019 | major depressive disorder | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT02789527 | Nov 2015 → Apr 2017 | — | Estella S. Poloni | Completed | No outcome recorded |
| — | NCT02502877 | Jul 2015 → Mar 2016 | — | Hospital da Luz, Portugal | Completed | No outcome recorded |
| — | NCT03237806 | May 2015 → Jan 2018 | acute respiratory distress syndrome | Southeast University, China | Completed | No outcome recorded |
| — | NCT02439164 | May 2015 → Mar 2017 | glioma | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT02438072 | Dec 2014 → Dec 2015 | depressive disorder | University Hospital, Geneva | Unknown | No outcome recorded |
| — | NCT02419547 | Jul 2014 → Apr 2015 | ventricular tachycardia | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT02134327 | Apr 2014 | delirium | Nemours Children's Clinic | Withdrawn | No outcome recorded |
| — | NCT02056236 | Apr 2014 → Apr 2021 | cardiac arrest | University of Twente | Completed | No outcome recorded |
| — | NCT01979653 | Nov 2013 | — | Severance Hospital | Withdrawn | No outcome recorded |
| — | NCT01945476 | Sep 2013 → Aug 2014 | breast cancer | Yonsei University | Completed | No outcome recorded |
| — | NCT02174588 | Jan 2013 → Feb 2015 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01680471 | Jul → Nov 2012 | delirium | Korea University Anam Hospital | Completed | No outcome recorded |
| — | NCT03563287 | Jan 2012 → Dec 2014 | morbid obesity | University of Eastern Finland | Completed | No outcome recorded |
| — | NCT01361217 | Sep 2011 → Jun 2012 | — | University of Washington | Completed | No outcome recorded |
| — | NCT01472835 | Mar 2011 → Feb 2013 | arthritis, sacroiliac | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT01618396 | Mar → Aug 2011 | infectious disease with sepsis | Casa de Saúde São José | Completed | No outcome recorded |
| — | NCT01315158 | Jan 2011 → Jul 2014 | obesity disorder, obstructive sleep apnea syndrome | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT01333059 | Sep 2010 → Oct 2012 | respiratory failure | Javier Gelvez, MD | Terminated | No outcome recorded |
| — | NCT01173640 | Jul 2010 → Feb 2011 | — | University of Washington | Completed | No outcome recorded |
| — | NCT01147146 | Jun → Dec 2010 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01053871 | Jan → May 2010 | functional gastric disease, gastritis | Shandong University | Completed | No outcome recorded |
| — | NCT00783731 | Oct 2008 → Oct 2010 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT00441792 | Oct 2007 → Dec 2010 | infectious disease with sepsis | Advocate Hospital System | Completed | No outcome recorded |
| — | NCT00675909 | Nov 2006 → Dec 2009 | anxiety | Seattle Children's Hospital | Completed | No outcome recorded |
| — | NCT00894465 | Aug 2006 → Jun 2009 | vesicoureteral reflux | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT00337792 | Jun 2006 → Jul 2007 | — | Planned Parenthood League of Massachusetts | Terminated | No outcome recorded |
| — | NCT01491009 | May 2006 → Feb 2007 | — | Gazi University | Completed | No outcome recorded |
| — | NCT00563069 | Sep 2005 → Dec 2006 | — | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| — | NCT00261261 | Jan 2001 → Dec 2004 | anxiety | Yale University | Completed | No outcome recorded |
| — | NCT00004424 | Jul 1996 → Mar 2000 | respiratory system disorder | FDA Office of Orphan Products Development | Completed | No outcome recorded |
Also used as a comparator or background therapy in 559 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07502651 Comparator | May 2025 → Mar 2027 expected | — | Postgraduate Institute of Dental Sciences Rohtak | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT07040163 Background | Mar 2025 → Feb 2026 overdue | — | CAMC Health System | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06368219 Comparator | Apr → Sep 2024 | — | Alexandria University | Unknown | No outcome recorded |
| Phase 0 | NCT05344495 Comparator | Jan → Jul 2022 | neuropathy, painful | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT04326738 Comparator | Jan → Apr 2020 | — | Yangzhou University | Completed | No outcome recorded |
| Phase 0 | NCT03165500 Comparator | Dec 2015 → Dec 2016 | anxiety disorder | São Paulo State University | Completed | No outcome recorded |
| Phase 0 | NCT02414932 Comparator | Apr 2015 → Apr 2017 | depressive disorder | St Patrick's Hospital, Ireland | Completed | No outcome recorded |
| Phase 0 | NCT02317341 Comparator | Dec 2014 → Mar 2019 | cancer | National Institute of Nursing Research (NINR) | Terminated | No outcome recorded |
| Phase 142 trials | ||||||
| Phase 1 | NCT07656792 Background | Jul → Nov 2026 expected | — | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06916702 Background | Apr 2025 → Oct 2026 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06917898 Comparator | Apr 2025 → Apr 2026 overdue | — | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06716190 Background | Dec 2024 → May 2025 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT06704763 Background | Dec 2024 → Feb 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06653244 Comparator | Apr → Dec 2024 | — | Menoufia University | Completed | No outcome recorded |
| Phase 1 | NCT06153355 Background | Dec 2023 → May 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06006598 Background | Aug 2023 → May 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05903963 Comparator | May → Nov 2023 | kidney failure | Minia University | Unknown | No outcome recorded |
| Phase 1 | NCT05866055 Background | May 2023 → Apr 2024 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05872087 Comparator | Nov 2022 → Sep 2023 | delirium | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT05573230 Background | Oct 2022 → Jan 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05518734 Background | Sep 2022 → Mar 2023 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05337085 Comparator | Jun → Dec 2022 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 1 | NCT05026567 Comparator | May → Jul 2022 | — | Crossject | Completed | No outcome recorded |
| Phase 1 | NCT05327595 Background | May 2022 → Apr 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05314569 Comparator | Apr → Sep 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT05032950 Comparator | Sep → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04767035 Comparator | Dec 2020 → Jan 2021 | — | Melt Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04454424 Background | Jul 2020 → Jun 2021 | diabetic neuropathy, endometriosis, overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04485702 Comparator | Jul → Aug 2020 | — | Melt Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04310579 Comparator | Jun 2020 → May 2021 | respiratory underresponsiveness to hypoxia and hypercapnia | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT04082858 Comparator | Jan → Jun 2020 | major depressive disorder | St Patrick's Hospital, Ireland | Terminated | No outcome recorded |
| Phase 1 | NCT03918187 Comparator | Apr → Aug 2019 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1 | NCT02401074 Background | Nov 2018 → Jun 2020 | asthma | Lu Yuan Lee | Withdrawn | No outcome recorded |
| Phase 1 | NCT03493269 Background | Apr 2018 → Sep 2020 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03256162 Comparator | Sep 2017 → Sep 2018 | bipolar depression, major depressive disorder | St Patrick's Hospital, Ireland | Completed | No outcome recorded |
| Phase 1 | NCT03199339 Comparator | Aug 2017 → Jul 2018 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 1 | NCT06867068 Comparator | Oct 2016 → Jun 2024 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02661061 Comparator | Dec 2015 → May 2018 | major depressive disorder | St Patrick's Hospital, Ireland | Terminated | No outcome recorded |
| Phase 1 | NCT04110535 Comparator | Jun → Oct 2015 | substance abuse | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02432664 Comparator | Apr 2015 → Apr 2016 | — | Orion Corporation, Orion Pharma | Terminated | No outcome recorded |
| Phase 1 | NCT01970072 Comparator | Oct 2013 → Jun 2014 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01296555 Background | Mar 2011 → Jun 2021 | non-Hodgkin lymphoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01570569 Comparator | Jan → Mar 2011 | — | Inje University | Completed | No outcome recorded |
| Phase 1 | NCT01221727 Comparator | Nov 2010 → Jul 2011 | postmenopausal osteoporosis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT01187862 Background | Jul 2010 → Feb 2011 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01162486 Comparator | Apr 2010 → Feb 2011 | pulmonary tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01393990 Background | Sep 2008 → Feb 2013 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00692510 Background | Nov 2007 → Sep 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01743300 Comparator | Jul 2007 → Dec 2010 | — | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00534378 Comparator | Jul → Dec 2006 | epilepsy | U.S. Army Office of the Surgeon General | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT07443254 Background | Mar 2026 → Apr 2027 expected | — | CAMC Health System | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06126991 Background | Jan → Dec 2024 | — | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04955470 Comparator | Jun 2022 → Sep 2023 | — | University of British Columbia | Terminated | No outcome recorded |
| Phase 1/2 | NCT05610969 Comparator | Sep 2021 → May 2023 | anxiety, peripheral nerve lesion | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1/2 | NCT04033471 Comparator | Jul 2019 → Mar 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04242914 Background | Feb 2019 → Feb 2021 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT02935959 Comparator | Oct 2016 → Sep 2017 | childhood malignant neoplasm | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT02367170 Background | Mar → Jul 2015 | infectious disease with sepsis | University of Florida | Terminated | No outcome recorded |
| Phase 1/2 | NCT02065947 Background | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01944293 Comparator | Sep 2013 → Sep 2017 | bipolar disorder, depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01371110 Comparator | Jun 2012 → Jun 2015 | obsessive-compulsive disorder | Wayne Goodman MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT01535937 Comparator | Feb 2012 → Jan 2017 | cocaine dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01404442 Comparator | May → Nov 2011 | — | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 251 trials | ||||||
| Phase 2 | NCT07569198 Comparator | Jun 2026 → Jan 2029 expected | bipolar depression, borderline personality disorder, major depressive disorder | Joshua Rosenblat | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06835101 Comparator | Feb → Dec 2025 overdue | — | Asklepieion Voulas General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06330584 Comparator | Dec 2024 → Sep 2025 overdue | anxiety | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 2 | NCT06496750 Comparator | Sep 2024 → Aug 2026 overdue | substance abuse | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06275594 Comparator | Mar 2024 → Feb 2025 | — | Yeungnam University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06480500 Comparator | Jan 2024 → Mar 2026 overdue | major depressive disorder | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT05737693 Comparator | Aug 2023 → Aug 2030 expected | post-traumatic stress disorder | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT05004896 Comparator | Jul 2022 → Nov 2025 | bipolar I disorder, bipolar II disorder, bipolar depression | Joshua Rosenblat | Completed | No outcome recorded |
| Phase 2 | NCT05046184 Comparator | May 2022 → Apr 2025 | major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04613453 Comparator | Jan 2022 → Jul 2024 | — | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT04378426 Comparator | Oct 2021 → Aug 2022 | post-traumatic stress disorder | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 2 | NCT04912115 Comparator | Oct 2021 → Dec 2023 | central nervous system disorder, movement disorder | PharmaTher Inc. | Suspended | No outcome recorded |
| Phase 2 | NCT05133518 Comparator | Jul 2021 → Oct 2022 | cataract | Melt Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04926844 Background | Jun 2021 → Aug 2022 | epilepsy with generalized tonic-clonic seizures | Sohag University | Completed | No outcome recorded |
| Phase 2 | NCT05186454 Comparator | May 2021 → Feb 2022 | — | Sohag University | Unknown | No outcome recorded |
| Phase 2 | NCT04873596 Comparator | May 2021 → Jun 2024 | — | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT05383313 Comparator | May 2021 → Apr 2025 | — | National Institute of Mental Health, Czech Republic | Unknown | No outcome recorded |
| Phase 2 | NCT04149626 Comparator | Jan 2020 → Dec 2021 | — | Asklepieion Voulas General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04173962 Comparator | Aug 2019 → Mar 2021 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT03989609 Comparator | Jun 2019 → Feb 2020 | infectious disease with sepsis | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05078372 Comparator | Jan 2019 → Jan 2021 | — | Autonomous University of Nuevo León | Completed | No outcome recorded |
| Phase 2 | NCT04072328 Comparator | Oct 2018 → Aug 2020 | — | DongGuk University | Completed | No outcome recorded |
| Phase 2 | NCT03133780 Comparator | Jul 2018 → Mar 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03375671 Comparator | May 2018 → Mar 2020 | — | David Barbic | Completed | No outcome recorded |
| Phase 2 | NCT03448068 Background | Apr 2018 → Jan 2020 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03461718 Background | Mar 2018 → Oct 2019 | — | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03827408 Comparator | Nov 2017 → Aug 2019 | — | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2 | NCT03185819 Comparator | Oct 2017 → Mar 2023 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03185351 Comparator | Jun 2017 → Sep 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03084536 Comparator | Jun 2017 → Feb 2021 | female breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02992496 Comparator | Apr 2017 → Dec 2020 | major depressive disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT03054844 Background | Apr → Oct 2017 | — | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02624596 Comparator | Jun 2016 → Jun 2026 overdue | obsessive-compulsive disorder | Stanford University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02727998 Comparator | Dec 2015 → Nov 2021 | post-traumatic stress disorder | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT02946437 Comparator | Nov 2015 → Dec 2019 | acquired aneurysmal subarachnoid hemorrhage | University of Zurich | Withdrawn | No outcome recorded |
| Phase 2 | NCT02351869 Comparator | Aug 2015 → Feb 2020 | bipolar disorder | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| Phase 2 | NCT02206776 Comparator | Sep 2014 → May 2015 | obsessive-compulsive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02172014 Background | Jun 2013 → Jan 2015 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01687751 Comparator | Nov 2012 → Nov 2014 | delirium | Fraser Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT01691690 Background | Oct 2012 → Nov 2015 | tonsillitis | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01845441 Comparator | Apr 2012 → Dec 2021 | brain ischemia, intracranial vasospasm, stroke disorder | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01503788 Comparator | Feb 2012 → Feb 2014 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02284204 Background | Jan 2012 → Aug 2014 | — | Federal University of Goiás | Completed | No outcome recorded |
| Phase 2 | NCT01567657 Comparator | Jan 2012 → Jan 2013 | hypotensive disorder | Kantonsspital Münsterlingen | Completed | No outcome recorded |
| Phase 2 | NCT01402596 Comparator | Aug 2011 → Aug 2012 | traumatic brain injury | University of Sao Paulo | Withdrawn | No outcome recorded |
| Phase 2 | NCT01145222 Comparator | May → Sep 2010 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00749203 Comparator | Jan 2009 → Sep 2013 | depressive disorder, post-traumatic stress disorder | Dennis Charney | Completed | No outcome recorded |
| Phase 2 | NCT00652028 Background | Nov 2008 → Apr 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00768430 Comparator | Nov 2008 → Sep 2012 | major depressive disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00326612 Comparator | Jun 2006 → Dec 2008 | epilepsy | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00581139 Comparator | Apr 2003 → Apr 2009 | adenoid hypertrophy, neuropathy, painful, tonsillitis | University of California, Irvine | Completed | No outcome recorded |
| Phase 2/321 trials | ||||||
| Phase 2/3 | NCT07057752 Comparator | Aug → Oct 2025 | peripheral arterial disease | Kastamonu University | Completed | No outcome recorded |
| Phase 2/3 | NCT03223220 Background | Jul 2024 → Dec 2026 expected | ischemic stroke | Lower Merion Neurology Research Foundation | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05779657 Background | Mar 2023 → Aug 2024 | epilepsy with generalized tonic-clonic seizures | Sohag University | Completed | No outcome recorded |
| Phase 2/3 | NCT04704622 Comparator | Jan → Feb 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT03436121 Background | Dec 2019 → Feb 2020 | depressive disorder | Maria Pacella | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03889756 Comparator | Jul → Dec 2019 | major depressive disorder | Yale University | Terminated | No outcome recorded |
| Phase 2/3 | NCT03592537 Comparator | Aug 2018 → Apr 2021 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03407404 Background | Oct 2017 → Jun 2019 | — | Makerere University | Terminated | No outcome recorded |
| Phase 2/3 | NCT03725995 Background | Jun 2017 → Jan 2018 | — | Latakia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03458078 Comparator | Feb → Jun 2017 | — | Centre de Maternité de Monastir | Completed | No outcome recorded |
| Phase 2/3 | NCT03130842 Comparator | Sep 2016 → Feb 2017 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02397889 Comparator | May 2015 → Jan 2020 | post-traumatic stress disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2/3 | NCT02619799 Comparator | Jan → Dec 2015 | — | Rangaraya Medical College | Completed | No outcome recorded |
| Phase 2/3 | NCT02398136 Comparator | Dec 2014 | post-traumatic stress disorder | Adriana Feder | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02065843 Comparator | Mar → Apr 2014 | impacted teeth, multiple | Federal University of Sergipe | Completed | No outcome recorded |
| Phase 2/3 | NCT01945047 Comparator | May 2013 → Dec 2017 | — | University of Ottawa | Completed | No outcome recorded |
| Phase 2/3 | NCT01807429 Background | Dec 2012 → Jan 2013 | dwarfism thin bones multiple fractures | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01508455 Background | Mar → May 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT01188551 Background | Jan 2011 → Apr 2012 | chronic otitis media | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01159262 Background | Jul 2010 → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT00109395 Comparator | Sep 2004 → Sep 2007 | — | The Emmes Company, LLC | Completed | No outcome recorded |
| Phase 364 trials | ||||||
| Phase 3 | NCT07542990 Comparator | Apr 2026 → Apr 2029 expected | delirium | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07336095 Comparator | Mar → Jun 2026 overdue | anxiety, subacute delirium | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07262008 Comparator | Feb 2026 → Feb 2027 expected | major depressive disorder | Women's College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07227454 Comparator | Jan 2026 → Apr 2031 expected | major depressive disorder | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06878703 Comparator | Oct 2025 → Dec 2027 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07113483 Comparator | Oct 2025 → Jan 2026 overdue | — | Romanian Society for Enteral and Parenteral Nutrition | Recruiting | No outcome recorded |
| Phase 3 | NCT07184801 Comparator | Oct 2025 → Oct 2026 expected | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 3 | NCT07099014 Comparator | Sep 2025 → Oct 2028 expected | cardiogenic shock | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07013955 Comparator | Apr → Nov 2025 overdue | — | Minia University | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06752759 Comparator | Oct 2024 → Sep 2027 expected | major depressive disorder | Theresa Jacob, PhD, MPH | Recruiting | No outcome recorded |
| Phase 3 | NCT05625555 Comparator | Jan 2024 → Jul 2026 overdue | bipolar disorder, major depressive disorder | Abraham Nunes | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06122948 Comparator | Nov 2023 → Oct 2024 | adenoid hypertrophy, drug allergy, tonsillitis | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05836545 Comparator | Apr 2023 → Jan 2024 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05340803 Comparator | Nov 2022 → Jan 2025 | traumatic brain injury | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT04592809 Comparator | Oct 2022 → Jul 2025 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05346666 Background | Jun 2022 → Sep 2023 | epilepsy | Damanhour University | Unknown | No outcome recorded |
| Phase 3 | NCT05485519 Comparator | Apr 2022 → May 2024 | substance withdrawal syndrome | King Abdullah International Medical Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT05192629 Comparator | Mar 2022 → Jun 2023 | — | Brugmann University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05220462 Comparator | Mar 2022 → May 2024 | — | Guy's and St Thomas' NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT05263674 Background | Feb 2022 → Dec 2027 expected | epilepsy | University of Southern Denmark | Recruiting | No outcome recorded |
| Phase 3 | NCT05958589 Background | Jan 2022 → Jul 2024 | — | University of Novi Sad | Completed | No outcome recorded |
| Phase 3 | NCT04356638 Comparator | Oct 2021 → Dec 2023 | anxiety | King Faisal Specialist Hospital & Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT04939649 Comparator | Sep 2021 → Apr 2024 | bipolar depression, major depressive disorder | University of Dublin, Trinity College | Completed | No outcome recorded |
| Phase 3 | NCT04082767 Comparator | Jun 2021 → Sep 2024 | — | Douglas Fraser | Unknown | No outcome recorded |
| Phase 3 | NCT04621110 Comparator | Jun → Sep 2021 | childhood malignant neoplasm | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04801589 Comparator | May 2021 → Apr 2026 overdue | delirium, post-traumatic stress disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT04684238 Comparator | Jan 2021 → Jan 2023 | — | Sedana Medical | Completed | No outcome recorded |
| Phase 3 | NCT04355962 Comparator | Apr 2020 → Jun 2021 | COVID-19, acute respiratory distress syndrome | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT04197570 Comparator | Feb → Mar 2020 | substance-related disorder | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT06185127 Comparator | Sep 2019 → May 2020 | lung disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT03844984 Background | Feb → Sep 2019 | infectious disease with sepsis | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03640468 Background | Dec 2018 → Jun 2019 | infectious disease with sepsis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT03728894 Comparator | Nov 2018 → Jan 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 3 | NCT03513822 Comparator | Feb → Oct 2018 | chronic pain syndrome, neuralgia | Redar | Unknown | No outcome recorded |
| Phase 3 | NCT03016819 Comparator | Aug 2017 → Dec 2027 expected | alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT03171740 Comparator | Jun → Dec 2017 | delirium | Brasilia University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03069677 Comparator | Apr 2017 → May 2018 | anxiety | University of Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT02801201 Comparator | May 2016 → Dec 2024 | — | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT02509273 Comparator | May 2016 → Oct 2018 | — | University of Erlangen-Nürnberg Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT03388151 Comparator | Apr 2016 → Nov 2022 | cirrhosis of liver | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02532647 Comparator | Nov 2015 → Dec 2016 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02556606 Comparator | Oct 2015 → Mar 2020 | major depressive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT02466022 Background | Jun → Nov 2015 | — | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT02296892 Comparator | Apr 2015 → Mar 2017 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02290873 Comparator | Mar 2015 → Apr 2016 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03650270 Background | Mar 2015 → Mar 2018 | epilepsy | University of Cape Town | Completed | No outcome recorded |
| Phase 3 | NCT02250703 Comparator | Sep 2014 → Sep 2016 | — | University of Mississippi Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02096900 Comparator | Jul 2014 → May 2016 | anxiety | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT04686058 Comparator | Mar → Dec 2014 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT02325583 Background | Jan → Oct 2014 | epilepsy, hydrocephalus | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT02444260 Comparator | Dec 2013 → Dec 2015 | — | The University of The West Indies | Unknown | No outcome recorded |
| Phase 3 | NCT02192710 Comparator | May 2013 → Apr 2014 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT01802255 Comparator | Mar 2013 → Jan 2015 | poisoning | F Javier Belda | Withdrawn | No outcome recorded |
| Phase 3 | NCT02658721 Background | Jan → Jun 2013 | — | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01837290 Comparator | Dec 2012 → Jan 2014 | chronic renal failure syndrome, osteoporosis | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT01768377 Background | Nov 2012 → Feb 2013 | — | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02058485 Comparator | Jan 2012 → Apr 2013 | hypertensive disorder | Duzce University | Completed | No outcome recorded |
| Phase 3 | NCT01517828 Comparator | Jan 2012 → May 2016 | respiratory distress syndrome in premature infants | University Hospital, Montpellier | Unknown | No outcome recorded |
| Phase 3 | NCT01091818 Comparator | Mar 2010 → Oct 2011 | — | Ullevaal University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00875550 Comparator | Jan 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00542542 Comparator | Sep 2007 → Mar 2014 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00481312 Comparator | Jun 2007 → Aug 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00336882 Comparator | Jun 2006 → Oct 2009 | traumatic brain injury | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00290082 Comparator | Dec 2005 → Oct 2007 | — | University Hospital, Rouen | Terminated | No outcome recorded |
| Phase 4194 trials | ||||||
| Phase 4 | NCT07637279 Comparator | Nov 2026 → Jun 2028 expected | polyp of large intestine | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07368738 Background | Apr 2026 → Apr 2027 expected | — | Horizon Health Network | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07427446 Comparator | Feb → Dec 2026 expected | delirium | Kasr El Aini Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07425444 Comparator | Feb 2026 → Feb 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07265128 Comparator | Dec 2025 → Sep 2027 expected | delirium | Yonsei University | Not yet recruiting | No outcome recorded |
| Show all 194 trials opens the full record — a long page | ||||||
| Phase not applicable166 trials | ||||||
| — | NCT06727435 Background | Aug 2026 → Apr 2028 expected | — | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07706725 Background | Jul → Sep 2026 expected | — | Adiyaman University Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07565116 Comparator | May → Aug 2026 overdue | — | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07558226 Comparator | May 2026 → Nov 2027 expected | — | Fundacio Puigvert | Recruiting | No outcome recorded |
| — | NCT07519694 Comparator | May → Jun 2026 overdue | — | Sohag University | Not yet recruiting | No outcome recorded |
| Show all 166 trials opens the full record — a long page | ||||||
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 1,205 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Midazolam | “Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to...” NCT02219659 ↗1180“We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 2023 “The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given...” NCT05121324 ↗ “Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17 and an oral dose of CYP cocktail (CYP2B6 [bupropion 20 mg], CYP2C8 [repaglinide 0.05 mg], CYP2C9...” NCT07259330 ↗ “Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ “In this DDI part, each subject (n=14) will be administered midazolam (2 mg suspension) and bupropion (150 mg, tablet) together on Day 1, followed by a 7-day washout, followed...” NCT03199339 ↗ “A CYP probe cocktail composed of approved, commercially available drugs (caffeine, flurbiprofen, omeprazole, and midazolam) will be administered concomitantly as a single-dose...” NCT07426042 ↗ “Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6),...” PMID 24722393 ↗ Apr 2014 “The BTZ-043 groups also received oral dolutegravir (a third of participants) or a probe drug cocktail (caffeine [probe for CYP1A2], tolbutamide [CYP2C9], dextromethorphan...” PMID 39793592 ↗ Jan 2025 “The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed...” NCT03546088 ↗ “In this study, it was aimed to investigate electrophysiologic effects of cardiac autonomic system by using HRV analysis in dexmedetomine and midazolam patients who underwent...” NCT03601091 ↗ “Standard Medical Therapy include continuous intravenous infusion of an anesthetic agent, such as midazolam (starting regimen: 0.2 mg/kg IV bolus followed by continuous infusion...” NCT07496749 ↗ “A single dose of selective substrates (probe drugs) was administered orally on days 15 and 30: caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan...” PMID 37768317 ↗ Sep 2023 “Participants will take a combination of 3 drugs (omeprazole 20 mg capsule, tolbutamide 500 mg tablet, and midazolam 2mg/mL liquid) orally (by mouth) or 2 tablets of study drug...” NCT01147887 ↗ “Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO)...” NCT07704658 ↗ “CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗ “The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in...” NCT06975605 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the...” NCT06429657 ↗ “Midazolam 0.03 mg/kg injection vein,Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium...” NCT02644980 ↗ “Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and...” NCT01011634 ↗ “Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion” NCT03129009 ↗ “to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.” NCT06464263 ↗ “Oral midazolam, a short-acting benzodiazepine, is commonly used as a standard premedication in children due to its well-established anxiolytic, sedative, and amnestic effects.” NCT07345715 ↗ “The Effect of Tasisulam on CYP3A-mediated Metabolism of Midazolam: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Tumors or Lymphoma” NCT01209832 ↗ “general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.” NCT03569046 ↗ “Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.” NCT02592317 ↗ “Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.” NCT02819102 ↗ “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 “both midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) were given intravenously” NCT01321047 ↗ “may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion” NCT03263117 ↗ “Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.” NCT02688088 ↗ “Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1.” NCT02686164 ↗ “To compare the single-dose pharmacokinetic profile of midazolam 5 mg when administered alone vs. when administered with a single-dose of lurasidone 120 mg.” NCT01082263 ↗ “ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)” NCT06930872 ↗ “Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.” NCT05263674 ↗ “The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗ “Local anesthesia (e.g., 2% Lidocaine) and conscious sedation (e.g., Fentanyl and Midazolam) will be administered to the patient during the procedure” NCT06426992 ↗ “general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg” NCT02154074 ↗ “Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)” NCT05657613 ↗ “For the purposes of enrollment and analysis all benzodiazepines used for sedation (mainly midazolam and lorazepam) will be considered equivalent.” NCT00826553 ↗ “Midazolam (0.075 mg/kg orally) with collection of 8 plasma samples over 6 hours (only for Phase 1) to determine CYP3A activity (MDZ CL/F mL/min).” NCT00164112 ↗ “Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.” NCT06533280 ↗ “Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).” NCT06693960 ↗ “Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation” NCT03653520 ↗ “Deep sedation(Propofol Injectable Emulsion or Midazolam Injection) combined with intermittent bolus injection of muscle relaxants is used” NCT05658692 ↗ “A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects” NCT02841761 ↗ “received dental treatment while sedated with midazolam combined with the systemized communication technique "The Four Habits Model"” PMID 37349747 ↗ Jun 2023 “Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine” NCT04355962 ↗ “Midazolam nasal spray (MDZ-NS) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity” PMID 33140403 ↗ Nov 2020 “probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).” NCT00401583 ↗ “Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation” NCT05863455 ↗ “The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine.” PMID 32851583 ↗ Nov 2020 “Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)” NCT04201197 ↗ “Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg” NCT04233437 ↗ “The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.” NCT04538573 ↗ “Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies” NCT00420615 ↗ “Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally” NCT03718884 ↗ “Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20” NCT01001299 ↗ “Anesthesia induction will include 2 mg midazolam, 2-2.5 mg/kg propofol, 0.6-0.9 mg/kg rocuronium, and 1 μg/kg remifentanil.” NCT07271472 ↗ “patients will be premedicated with the undiluted IV formulation of Midazolam (5 mg/mL), 0.5 mg/kg up to 15 mg per patient.” NCT04991298 ↗ “Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.” NCT02289391 ↗ “1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)” NCT02590185 ↗ “Intravenous midazolam administered for procedural sedation during cataract surgery performed under topical anesthesia.” NCT07347886 ↗ “Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine.” NCT06383273 ↗ “Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection” NCT02123355 ↗ “For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.” NCT02147678 ↗ “GA will be induced with midazolam 1-2 mg, fentanyl 2μ/kg and propofol titrated to achieve loss of consciousness.” NCT03013075 ↗ “The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane.” NCT02058511 ↗ “All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.” NCT02399397 ↗ “CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab” PMID 39707077 ↗ Dec 2024 “oral dose of the Cooperstown Cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan)” NCT02434861 ↗ “Rescue hypnotic sedation with midazolam or propofol is permitted for safety and clinical necessity.” NCT06727435 ↗ “On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally.” NCT05958589 ↗ “Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg).” NCT02401074 ↗ “intravenous premedication (midazolam 2 mg and 4mg ondansetron) was administered to all patients” NCT04365686 ↗ “A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol” NCT01566838 ↗ “a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam” NCT03650270 ↗ “midazolam (administered intravenously at a dosage of 1 mg, up to a maximum dose of 3 mg)” NCT06653244 ↗ “Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam.” NCT02534012 ↗ “BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)” NCT03561298 ↗ “GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam” NCT02567682 ↗ “Warfarin and midazolam will be co-administered alone and in combination with ZSP1273.” NCT05942365 ↗ “All patients aged between 6 months-10 years were administered midazolam and atropine.” NCT02931786 ↗ “Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg” NCT04894864 ↗ “the following benzodiazepines (bolus + continuous infusion): lorazepam or midazolam” NCT02056236 ↗ “Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg)” NCT05126459 ↗ “a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam)” NCT06549426 ↗ “Caffeine + Warfarin (plus vitamin K) + Omeprazole + Dextromethorphan + Midazolam” NCT02993471 ↗ “Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg” NCT01443039 ↗ “Partecipants receive premedication with midazolam 0,02 mg/kg intravenous.” NCT05417529 ↗ “includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan” NCT03505853 ↗ “Sedation will be administered using low-dose midazolam and/ or fentanyl.” NCT04887285 ↗ “May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation.” NCT00878345 ↗ “Midazolam 2 mg as slow intravenous bolus immediately prior to procedure” NCT02713191 ↗ “Inj.midazolam 5mg/ml given to participants in infusion form for 24 hrs” NCT05264077 ↗ “Midazolam will be given as needed in bolus doses if agitation occurs.” NCT07620912 ↗ “typically 0-2 mg of IV midazolam at the discretion of the care team.” NCT05509192 ↗ “Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion” NCT03778723 ↗ “caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole” NCT03720366 ↗ “Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)” NCT03237806 ↗ “patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg)” NCT00413582 ↗ “midazolam 0,1 mgkg-1 intravenously (anesthesia induction)” NCT02840526 ↗ “routine iv premedication (midazolam 0.03 mg/kg) was given” NCT02001948 ↗ “Midazolam will be given in doses of 1-2 mg intravenously.” NCT07637279 ↗ “dextromethorphan, caffeine, omeprazole, and midazolam” NCT05334108 ↗ “intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam” NCT02072083 ↗ “Continuous morphine/midazolam and 'as needed' doses.” NCT02112448 ↗ “Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV” NCT03448068 ↗ “1. Premedication 0.02mg/kg-0.1mg/kg of midazolam;” NCT02119806 ↗ “Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)” NCT03171740 ↗ “intravenous midazolam 2mg, propofol 2mg kg-1” NCT06493396 ↗ “Midazolam solution for oral administration.” NCT05123820 ↗ “Midazolam is a drug approved for anxiety.” NCT03831971 ↗ “midazolam 2mg IV x 1 as need for anxiety” NCT04197570 ↗ “Midazolam 0.015 mg/kg bolus IV PRN.” NCT01381627 ↗ “ * Midazolam * Levomepromazine” NCT02009306 ↗ “Midazolam 1 - 2 mg intravenously” NCT01511627 ↗ “Caffeine 200 mg Midazolam 2 mg” NCT05532358 ↗ “USL261 (intranasal midazolam)” NCT01529034 ↗ “* midazolam: 1 µg infused IV” NCT04764851 ↗ “intravenous midazolam 2mg” NCT06305221 ↗ “Midazolam (1 mg, N05CD08)” NCT02438072 ↗ “IV Fentanyl and midazolam” NCT06899724 ↗ “Midazolam, Midazolam APL” NCT05830799 ↗ “2 mg midazolam (CYP3As)” PMID 31099895 ↗ Jul 2019 “midazolam 0.05mg/kg iv” NCT06120439 ↗ “CYP3A4 Midazolam 1 mg” NCT04814498 ↗ “-Midazolam: 1 mg\ml” NCT02121951 ↗ “Midazolam: 1-2mg” NCT07558226 ↗ “Drug: Midazolam” NCT07570082 ↗ “Midazolam alone” NCT05133518 ↗ “Midazolam 7.5mg” NCT02056743 ↗ “Drug: Midazolam” NCT01636557 ↗ “Midazolam (2mg)” NCT00741468 ↗ “Midazolam” NCT03965728 ↗ “midazolam” NCT03029676 ↗ |
| Known as | Dormicum | “with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with...” NCT03078946 ↗6“Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side...” NCT00886106 ↗ “Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects...” NCT00789386 ↗ “Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).” NCT00511654 ↗ “Ketalar (Ketamin, Pfizer) and Dormicum (Midazolam, Roche)” NCT02732132 ↗ “2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)” NCT05026567 ↗ |
| Known as | Hypnovel | “Usual neuroleptanalgesic treatment Hypnovel and Locoregional anesthesia” NCT06185829 ↗1“Arm 1 : Hypnovel® (midazolam)” NCT02192710 ↗ |
| Known as | IN Midazolam | “IN Midazolam” NCT04571879 ↗ |
| Known as | MDZ | “Our aim was to compare the effects of midazolam (0.3 mg kg-1: MDZ) for premedication with age-appropriate tablet game apps (TAB) on children anxiety during and after ambulatory surgery.” PMID 28100529 ↗ Feb 20176“Patients in one of the groups (called MDZ) were initially sedated with a 0.05mg/Kg bolus dose of Midazolam.” NCT02878837 ↗ “OBJECTIVE: We compared DEX with midazolam (MDZ) when used as a sedative during EBUS-TBNA.” PMID 33122573 ↗ May 2021 “Participants will be administered Midazolam (MDZ) in the presence or absence of VX-407.” NCT06345755 ↗ “using single-dose midazolam (MDZ)” NCT01162486 ↗ “Midazolam group (MDZ)” NCT03827408 ↗ “Midazolam (MDZ)” NCT07670377 ↗ |
| Known as | MDZ-NS | “Midazolam nasal spray (MDZ-NS) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity” PMID 33140403 ↗ Nov 20201“a novel formulation of midazolam administered as a single-dose nasal spray (MDZ-NS)” PMID 31353457 ↗ Jul 2019 |
| Known as | MHOS/SHP615 | “A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings” NCT03336450 ↗ |
| Known as | MID | “The purpose of this study was to compare the perioperative effects of the intramuscular (i.m.) alpha 2 agonist, dexmedetomidine (DEX), and midazolam (MID) premedication.” PMID 7943770 ↗ Oct 19941“and midazolam (MID) 0.03 mg/kg” NCT02556606 ↗ |
| Known as | mida | “Dexmedetomidine/remifentanil (dex/remi group) and midazolam/remifentanil (mida/remi group) were infused 7 days apart.” PMID 17056949 ↗ Nov 2006 |
| Known as | Midazolam "Hameln" ATC-code: N05CD08 | “Midazolam "Hameln" ATC-code: N05CD08” NCT01934088 ↗ |
| Known as | Midazolam (Bukwang Pharm.Co., Ltd.) | “Midazolam (Bukwang Pharm.Co., Ltd.)” NCT01760642 ↗ |
| Known as | Midazolam (hypnovel) | “Midazolam (hypnovel)” NCT01731184 ↗ |
| Known as | MIDAZOLAM 15mg/3ml ATC N05CD08 MAN 65319 | “MIDAZOLAM 15mg/3ml ATC N05CD08 MAN 65319” NCT02909049 ↗ |
| Known as | Midazolam 1mg/ml Solution for Injection | “Midazolam 1mg/ml Solution for Injection” NCT01744184 ↗ |
| Known as | Midazolam = Dormicum | “Midazolam = Dormicum” NCT01567657 ↗ |
| Known as | Midazolam Braun | “The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.3 mg/kg ,...” NCT06887712 ↗ |
| Known as | Midazolam HCl | “Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.” NCT03360123 ↗ |
| Known as | Midazolam Hydrochloride | “55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.” NCT06480500 ↗17“Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam” NCT01873339 ↗ “Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride” NCT02473627 ↗ “2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)” NCT05026567 ↗ “Midazolam Hydrochloride 2Mg/mL Syrup” NCT03360123 ↗ “Drug: Midazolam Hydrochloride” NCT07569198 ↗ “Drug: Midazolam Hydrochloride” NCT02992496 ↗ “Drug: Midazolam Hydrochloride” NCT06496750 ↗ “Drug: Midazolam Hydrochloride” NCT06867068 ↗ “Drug: Midazolam Hydrochloride” NCT02953210 ↗ “Drug: Midazolam Hydrochloride” NCT00142493 ↗ “midazolam hydrochloride syrup” NCT07372625 ↗ “Drug: Midazolam Hydrochloride” NCT05004896 ↗ “Drug: Midazolam Hydrochloride” NCT03330990 ↗ |
| Known as | Midazolam Maleate | “SHR0302 Tablets + probe drugs (Midazolam Maleate Tablets + Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Repaglinide Tablets) + Vitamin K1 Tablets” NCT05392127 ↗ |
| Known as | Midazolam Mylan | “Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment” NCT02078336 ↗ |
| Known as | Midazolam oral solution | “Drug: Midazolam oral solution” NCT06407518 ↗ |
| Known as | Midazolam oral solution, YICHANG HUMANWELL PHARMACEUTICAL | “Midazolam oral solution, YICHANG HUMANWELL PHARMACEUTICAL” NCT06407518 ↗ |
| Known as | Midazolam Panpharma | “1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)” NCT02590185 ↗ |
| Known as | Midazolam, Dormire (Cristalia Lab, Sao Paulo, Brazil) | “Midazolam, Dormire ® (Cristalia Lab, Sao Paulo, Brazil)” NCT02284204 ↗ |
| Known as | Midazolam, Midazolam APL | “Midazolam, Midazolam APL” NCT05830799 ↗ |
| Known as | Midazolam-ratiopharm | “Midazolam/ Midazolam-ratiopharm” NCT03353857 ↗ |
| Known as | nMDZ | “OBJECTIVE: To compare the effectiveness of sedation by intranasal administration of midazolam (nMDZ) or ketamine (nKTM) for neonatal intubation.” PMID 28818854 ↗ Aug 2017 |
| Known as | SHP615 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03336450 ↗ |
| Known as | USL261 | “Midazolam Intranasal Spray (USL261)” NCT01999777 ↗ |
| Known as | Versed | “standard therapy at this institution which consists of Versed (generic name midazolam) (5 mg) plus fentanyl (100 mcgs) as well as succinylcholine for RSI” NCT00462644 ↗6“If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:” NCT01315158 ↗ “IV sedation with fentanyl and versed” NCT03187002 ↗ “Versed” NCT01691690 ↗ |
| Known as | Versed (Midazolam) | “Versed (Midazolam)” NCT01050699 ↗ |
| Known as | Versed(Registered Trademark) | “After one dose of the sedative midazolam (Versed(Registered Trademark)): Participants will take an 8-milligram dose of midazolam syrup by mouth.” NCT00050180 ↗ |
| Action | Inhibit | “midazolam, which is a GABA A receptor inhibitor” NCT01680471 ↗ |
| Modality | Small molecule | “the midazolam witch is a benzodiazepine with a sedative and anxiolytic action” NCT00416039 ↗ |
| Route | Oral | “Participants will take an 8-milligram dose of midazolam syrup by mouth.” NCT00050180 ↗ |